Expression and localization of urokinase-type plasminogen activator in human spinal column tumors

Clinical and Experimental Metastasis

Volumn 16, Issue 8, 1998, Pages 713-719

  Gokaslan, Ziya L ^a   Chintala, Shravan K ^a   York, Julie E ^a   Boyapati, Venkaiah ^a   Jasti, Sushma ^a   Sawaya, Raymond ^a   Fuller, Gregory ^a   Wildrick, David M ^a   Nicolson, Garth L ^b   Rao, Jasti S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b INSTITUTE FOR MOLECULAR MEDICINE   (United States)

Author keywords

Immunohistochemistry; Proteases; Spinal metastases; uPA

Indexed keywords

SERINE PROTEINASE; UROKINASE;

ARTICLE; BREAST CANCER; CELLULAR DISTRIBUTION; CHONDROSARCOMA; CHORDOMA; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LOCALIZATION; GIANT CELL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LUNG CANCER; MELANOMA; PROTEIN EXPRESSION; SPINE CANCER; SPINE METASTASIS; THYROID CANCER; ZYMOGRAPHY;

CHONDROSARCOMA; CHORDOMA; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRIN; GIANT CELL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; SPINAL NEOPLASMS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0032440121     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006528711499     Document Type: Article

References (33)

1. 1. Black P, 1979, Spinal metastasis: current status and recommended guidelines for management. Neurosurgery, 5, 726-46.
2. 2. Harrington KD, 1986, Metastatic disease of the spine. J Bone Joint Surg Am, 68, 1110-15.
3. 3. Sundaresan N, Galicich JH, Chu FC and Huvos AG, 1979, Spinal chordomas. J Neurosurg, 50, 312-19.
4. 4. Kostuik JP and Weinslein JN, 1991, Differential diagnosis and surgical treatment of metastastic spine tumors. In: Frymoyer JW, ed: The Adult Spine: Principles und Practice. New York: Raven Press, 861-88.
5. 5. Cummings BJ, Esses S and Harwood AR, 1982, The treatment of chordomas. Cancer Treat Rev, 9, 299-311.
6. 6. Shives TC, Wold LE, Dahlin DC and Beabout JW, 1983, Chondrosarcoma and its Variants. Diagnosis and Treatment of Bone Tumors: A Team Approach. Sim FH, ed. Thorofare, NJ: Slack, Inc., 211-12.
7. 7. Sanerkin NG, 1980, The diagnosis and grading of chondrosarcoma of bone: a combined cytologic and histologic approach. Cancer, 45, 582-94.
8. 8. Caballes RL, 1981, The mechanism of metastasis in the so-called 'benign giant cell tumor of bone'. Human Pathol, 12, 762-7.
9. 9. Rock MG, Prichard DJ and Unni KK, 1984, Metastasis from histologically benign giant-cell tumor of bone. J Bone Joint Surg Am, 66A, 269-74.
10. 10. Danø K, Andreasen PA, Grondahl-Hansen J, et al. 1985, Plasminogen activators, tissue degradation and cancer. Adv Cancer Res, 44, 139-266.
11. 11. Pollanen J, Stephens RW and Vaheri A, 1991, Directed plasminogen activation at the surface of normal malignant cells. Adv Cancer Res, 57, 273-328.
12. 12. Ossowski L, 1988, Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo. Cell, 52, 321-8.
13. 13. Liotta LA, Steeg PS and Stetler-Stevenson WG, 1991, Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64, 327-36.
14. 14. Reich R, Thompson EW, Iwamoto Y, et al. 1988, Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res, 48, 3307-12.
15. 15. de Bruin PA, Griffioen G, Verspaget HW, et al. 1988, Plasminogen activator profiles in neoplastic tissues of the human colon. Cancer Res, 48, 4520-4.
16. 16. Sappino AP, Busso N, Belin D and Vassalli JD, 1987, Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. Cancer Res, 47, 4043-6.
17. 17. Evers JL, Patel J, Madeja JM, et al. 1982, Plasminogen activator activity and composition in human breast cancer. Cancer Res, 42, 219-26.
18. 18. Janicke F. Schmitt M, Ulm K, et al. 1989, Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet, 2, 1049.
19. 19. Saito K, Nagashima M, Iwata M, et al. 1990, The concentration of tissue plasminogen activator and urokinase in plasma and tissues of patients with ovarian and uterine tumors. Thromb Res, 58, 355-66.
20. 20. Nishino N, Aoki K, Tokura Y, et al. 1988, The urokinase type of plasminogen activator in cancer of digestive tracts. Thromb Res, 50, 527-35.
21. 21. Ito Y, Takeda T, Kobayashi T, et al. 1996, Plasminogen activation system inactive even in thyroid tumors; an immunohistochemical study. Anticancer Res, 16, 81-89.
22. 22. Ito Y, Takeda T and Wakasugi E, 1995, Expression of urokinase-type plasminogen activator in various human thyroid tissues. Oncol Rep, 2, 525-28.
23. 23. Chiarodo A, 1991, National cancer institute roundtable on prostate cancer: Future research directions. Cancer Res, 51, 2498-2505.
24. 24. Cook GB and Watson FR, 1968, Events in the natural history of prostate cancer: using salvage curves, mean age distributions and contingency coefficients. J Urol, 99, 87-96.
25. 25. Achbarou A, Kaiser S, Tremblay G, et al. 1994, Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res, 54, 2372-77.
26. 26. Yamamoto M, Sawaya R, Mohanam S, et al. 1994, Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. Cancer Res, 54, 3656-61.
27. 27. Blasi F, 1993, Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasiveness. Bioessays, 15, 105-11.
28. 28. Pollanen J, Hedman K, Nielsen LS, et al. 1988, Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol, 106, 87-95.
29. 29. Stephens RW, Pollanen J, Tapiovaara H, et al. 1989, Activation of pro-urokinase and plasminogcn on human sarcoma cells: a proteolytic system with surface-hound reactants. J Cell Biol, 108, 1987-95.
30. 30. Isaacs JT, Isaacs WB, Feitz WF and Scheres J, 1986, Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate, 9, 261-81.
31. 31. Ray RD, 1976, Circulation and bone. In: Bourne GH, ed. The Biochemistry and Physiology of Bone. New York: Academic Press, Vol. 4, 385-402.
32. 32. Haq M, Goltzman D, Tremblay G and Brodt P, 1992, Rat prostate adenocarcinoma cells disseminate to bone and adhere preferentially to bone marrow-derived endothelial cells. Cancer Res, 52, 4613-19.
33. 33. Lang FF and Sawaya R, 1996, Surgical management of cerebral metastases. Neurosurg Clin N Am, 7, 459-84.